Combining tricyclic and monoamine oxidase inhibitor antidepressants.
The charts of 150 inpatients and 51 outpatients treated with a monoamine oxidase inhibitor (MAOI)-tricyclic antidepressant combination were reviewed. The incidence and severity of side effects among the patients on the combined regimen were essentially the same as those seen in the control groups. There were no deaths or strokes resulting from use of this regimen. The most frequent troublesome side effect was orthostatic hypotension. We conclude that the use of a MAOI-tricyclic combination in oral therapeutic doses is safe. However, the efficacy of this combination has not yet been proved, and it may be particularly toxic if taken in an overdose.
D000639:Amitriptyline / Q000008:administration & dosage; D000929:Antidepressive Agents, Tricyclic / Q000009:adverse effects / Q000627:therapeutic use*; D003863:Depression / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D006801:Humans; D006973:Hypertension / Q000139:chemically induced; D007022:Hypotension / Q000139:chemically induced; D007099:Imipramine / Q000008:administration & dosage; D007520:Isocarboxazid / Q000008:administration & dosage; D008996:Monoamine Oxidase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D010624:Phenelzine / Q000008:administration & dosage; D014191:Tranylcypromine / Q000008:administration & dosage
D000929:Antidepressive Agents, Tricyclic; D008996:Monoamine Oxidase Inhibitors; D000639:Amitriptyline; D007520:Isocarboxazid; D014191:Tranylcypromine; D010624:Phenelzine; D007099:Imipramine